This review seeks to examine the diagnostic and therapeutic relevance of inflammatory biomarkers – specifically interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) – and evaluate their potential for improving risk stratification and enabling personalized treatment approaches in HF. Here, IL6 is linked to hydrops fetalis.